Evidence map›Paper›PMID 34493279›Full record

ArticleBMC biology2021

ACBD3 modulates KDEL receptor interaction with PKA for its trafficking via tubulovesicular carrier.

Xihua Yue, Yi Qian, Lianhui Zhu, Bopil Gim, Mengjing Bao, Jie Jia, Shuaiyang Jing, Yijing Wang, Chuanting Tan, Francesca Bottanelli and 4 more

Open access · goldAbstract read
In one paragraph

Article in BMC biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 4 countries.

Xihua Yue *School of Life Science and Technology, ShanghaiTech University, Pudong, Shanghai, China.
Yi Qian *School of Life Science and Technology, ShanghaiTech University, Pudong, Shanghai, China.
Lianhui ZhuSchool of Life Science and Technology, ShanghaiTech University, Pudong, Shanghai, China.
Bopil GimSchool of Physical Science and Technology, ShanghaiTech University, Pudong, Shanghai, China.
Mengjing BaoSchool of Life Science and Technology, ShanghaiTech University, Pudong, Shanghai, China.
Jie JiaSchool of Life Science and Technology, ShanghaiTech University, Pudong, Shanghai, China.
Shuaiyang JingSchool of Life Science and Technology, ShanghaiTech University, Pudong, Shanghai, China.
Yijing WangSchool of Life Science and Technology, ShanghaiTech University, Pudong, Shanghai, China.
Chuanting TanSchool of Life Science and Technology, ShanghaiTech University, Pudong, Shanghai, China.
Francesca BottanelliInstitut für Biochemie, Freie Universität Berlin, Thielallee 63, 14195, Berlin, Germany.
Pascal ZiltenerDepartment of Cell Biology, Yale University School of Medicine, New Haven, CT, USA.
Sunkyu ChoiProteomics Core, Weill Cornell Medicine-Qatar, Doha, Qatar.
Piliang HaoSchool of Life Science and Technology, ShanghaiTech University, Pudong, Shanghai, China.
Intaek LeeSchool of Life Science and Technology, ShanghaiTech University, Pudong, Shanghai, China. Leeintaek@shanghaitech.edu.cn.ORCID 0000-0003-1084-674X
ShanghaiTech University · CNFreie Universität Berlin · DEWeill Cornell Medical College in Qatar · QAYale University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundKDEL receptor helps establish cellular equilibrium in the early secretory pathway by recycling leaked ER-chaperones to the ER during secretion of newly synthesized proteins. Studies have also shown that KDEL receptor may function as a signaling protein that orchestrates membrane flux through the secretory pathway. We have recently shown that KDEL receptor is also a cell surface receptor, which undergoes highly complex itinerary between trans-Golgi network and the plasma membranes via clathrin-mediated transport carriers. Ironically, however, it is still largely unknown how KDEL receptor is distributed to the Golgi at steady state, since its initial discovery in late 1980s.

resultsWe used a proximity-based in vivo tagging strategy to further dissect mechanisms of KDEL receptor trafficking. Our new results reveal that ACBD3 may be a key protein that regulates KDEL receptor trafficking via modulation of Arf1-dependent tubule formation. We demonstrate that ACBD3 directly interact with KDEL receptor and form a functionally distinct protein complex in ArfGAPs-independent manner. Depletion of ACBD3 results in re-localization of KDEL receptor to the ER by inducing accelerated retrograde trafficking of KDEL receptor. Importantly, this is caused by specifically altering KDEL receptor interaction with Protein Kinase A and Arf1/ArfGAP1, eventually leading to increased Arf1-GTP-dependent tubular carrier formation at the Golgi.

conclusionsThese results suggest that ACBD3 may function as a negative regulator of PKA activity on KDEL receptor, thereby restricting its retrograde trafficking in the absence of KDEL ligand binding. Since ACBD3 was originally identified as PAP7, a PBR/PKA-interacting protein at the Golgi/mitochondria, we propose that Golgi-localization of KDEL receptor is likely to be controlled by its interaction with ACBD3/PKA complex at steady state, providing a novel insight for establishment of cellular homeostasis in the early secretory pathway.

Indexed as

Adaptor Proteins, Signal TransducingGolgi ApparatusReceptors, PeptideCell MembraneCyclic AMP-Dependent Protein KinasesAdaptor Proteins, Signal TransducingCyclic AMP-Dependent Protein KinasesKDEL receptorReceptors, PeptideACBD3Arf1-GTPArfGAPsGolgiKDEL receptorProtein Kinase A

Identifiers

PMID34493279
PMCPMC8424950
OpenAlexW3197364593

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.